A

AstraZeneca

Global pharmaceutical company developing prescription medicines

Product Owner - Agentic Platform & Enterprise Interfaces

Full-TimeUpdated Deadline 11/26/26
No salary listed
Senior
Barcelona, Spain
In PersonIn-office in Barcelona; minimum three days per week on-site. Remote or travel flexibility is not available.
ProductTechnical Product Management

About the job

Requirements
  • At least five years of experience as a product owner or product manager of a technical platform, data platform, API, or developer-facing product.
  • Experience with LLM-based applications or agentic systems, including management of skills, tools, and connectors.
  • Working knowledge of APIs and integration patterns; familiarity with the Model Context Protocol is desirable.
  • Experience managing user access, onboarding, and support for an enterprise tool.
  • Understanding of information security and data access governance, ideally in a regulated environment.
  • Experience tracking usage and cost for cloud or AI services and making product decisions from the data.
  • Ability to prioritize a long request queue and communicate trade-offs clearly.
Responsibilities
  • Own the roadmap, backlog, and release priorities for the R&D agentic platform and its interfaces, working with engineering leads on scope and sequencing.
  • Decide what the platform should do itself and what should move to enterprise assistants as they mature.
  • Write product requirements, acceptance criteria, and release notes, and document decisions.
  • Own the skills library and marketplace, including intake, quality review, publication, retirement, and ownership of each skill.
  • Own the connector roadmap, including connectors to enterprise data and systems built on open standards such as the Model Context Protocol; prioritize requests against value, risk, and engineering capacity.
  • Set criteria for approving connectors and skills, and coordinate reviews before release with security, architecture, and data owners.
  • Define with data owners and security how users access data through the platform, including approval flows and criteria for patient-related data.
  • Track security findings to closure, including weaknesses in the handling of credentials, secrets, or conversations.
  • Keep access, audit, and retention requirements visible in the backlog and review them with Product Compliance.
  • Run intake and onboarding for new users and groups, including seat allocation and weekly review of access requests.
  • Work with support engineers and change partners on support queues, user communications, and training.
  • Handle business-area requests in flight and provide each with a clear answer and timeline.
  • Own platform usage and cost metrics, including model and token cost per session, and work with finance and platform teams on budgets and tiers.
  • Define and report value measures and user stories showing what the platform delivers in R&D.
  • Contribute to planning cycles with a clear view of run cost and options.
  • Work closely with AI scientists, engineers, Enterprise AI gateway and platform teams, security, architecture, and business sponsors.
  • Communicate what is shipping, what is blocked, and why, including when a request must wait.
Desired Qualifications
  • Experience in pharmaceutical or life sciences research and development.
  • Familiarity with FinOps practices for cloud or model usage.
  • Working knowledge of Atlassian tools, including JIRA and Confluence.
  • Familiarity with the Model Context Protocol.

About the company

AstraZeneca develops and markets prescription medicines and vaccines for global health, focusing on oncology, cardiovascular/metabolic, respiratory, and infectious diseases. Its products work by targeting specific biological pathways or cells to treat diseases or prevent infections, using small-molecule drugs, biologics, and vaccines. The company differentiates itself through its dual heritage from Sweden and the UK, a broad pipeline, and strong R&D with collaborations to move from discovery to patient access across multiple therapeutic areas. Its goal is to improve people’s health by discovering, developing, and delivering medicines and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Get referred to AstraZeneca

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Massachusetts expansion adds nearly 2,000 scientists and expands workforce over 50% by 2026.
  • H1 2026 revenue rose 6% to $30.7 billion, driven by oncology growth.
  • FLAURA2 and CLARITY-Gastric01 strengthened Tagrisso and sonesitatug vedotin in 2026.

What critics are saying

  • Farxiga faced US and Japan generic competition, plus China VBP, in H1 2026.
  • Forxiga patent fights continue in France, Poland, Portugal, and Australia through 2027.
  • Tagrisso dependence stays acute; one patent loss or trial failure would crush growth.

What makes AstraZeneca unique

  • Pascal Soriot doubled down on oncology, opening Cambridge R&D center October 5, 2026.
  • AstraZeneca's ADC and bispecific platform drove the $2 billion Summit Therapeutics deal September 28, 2026.
  • Tagrisso, Imfinzi, and rare disease franchises keep AstraZeneca diversified across high-value therapeutic categories.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Paid Vacation
  • Paid Holidays
  • Flexible Work Hours

Growth & Insights and Company News

6 month growth

6%

1 year growth

8%

2 year growth

8%
Yahoo Finance
Oct 30th, 2026
AstraZeneca shares jump 7% as cancer drugs lift Q3 revenue to $16.21B and $1.5B savings plan

AstraZeneca shares rose nearly 7% on Friday after the drugmaker beat earnings forecasts and announced a cost-cutting plan. Investors increasingly believe its cancer drugs can replace revenue lost to cheaper generic rivals. Third-quarter revenue rose 7% to $16.21 billion. Core earnings were $2.79 per share, against $2.59 expected. Oncology revenue jumped 17%, with Enhertu sales up 35% and Imfinzi up 26%. The company plans to save $1.5 billion a year, mainly to fund research, though restructuring could cost up to $2 billion upfront. Sales of diabetes and heart drug Farxiga fell 25% amid generic competition. Chief executive officer Pascal Soriot said AstraZeneca is on track for its 2030 goal of $80 billion in annual revenue.

Yahoo Finance
Oct 30th, 2026
AstraZeneca shares jump 7.65% as it plans $2B restructuring to unlock $1.5B in annual savings

AstraZeneca shares rose 7.65% to $187.75 at 12:40 ET on October 30, after the drugmaker announced a restructuring with one-time costs of up to $2 billion. The plan targets $1.5 billion in annualised pretax benefits. AstraZeneca will reinvest the savings, mainly in its development pipeline. Third-quarter revenue reached $16.21 billion, up 7% at constant currencies. Full-year guidance was unchanged. At the targeted savings, the maximum restructuring bill equals about 1.3 years of gross savings. That figure excludes reinvestment and timing of implementation, so the earnings benefit depends on when savings arrive and how quickly the company spends them.

Yahoo Finance
Oct 30th, 2026
AstraZeneca Q3 revenue rises 6.7% to $16.21B, beating estimates as EPS hits $2.79

AstraZeneca reported third-quarter revenue of $16.21 billion, up 6.7% from a year earlier. That beat the Zacks Consensus Estimate of $16.09 billion by 0.71%. Earnings per share rose to $2.79 from $2.38 a year ago, topping the $2.60 consensus by 7.31%. Cancer drug Tagrisso brought in $2.09 billion worldwide, up 12% and above the $1.98 billion estimate. Fasenra sales rose 13.6% to $602 million. Brilinta fell 48.6% to $75 million, and worldwide Symbicort sales dropped 10.2% to $666 million. Shares have gained 10.6% over the past month, against 0.7% for the Zacks S&P 500 composite.

Yahoo Finance
Oct 30th, 2026
AstraZeneca CEO eyes $20B+ from 2027 trial readouts as Q3 beats and $1.5B savings plan unveiled

AstraZeneca chief executive officer Pascal Soriot said the company's 2027 drug trial readouts could generate more than $20 billion in peak annual sales. The company has more than 180 projects in development, including treatments for cancer, respiratory illnesses, and rare diseases. Third-quarter revenue rose 7% to $16.21 billion, beating estimates of about $16 billion. Core earnings per share increased 17% to $2.79, against expectations of $2.59. Oncology revenue jumped 17% to $7.77 billion, while diabetes drug Farxiga sales fell 25% to $1.61 billion amid generic competition. AstraZeneca also announced a restructuring programme targeting $1.5 billion in annual savings by 2029, with up to $2 billion in one-time costs. Shares rose about 5% in pre-market trading.

Yahoo Finance
Oct 30th, 2026
AstraZeneca profit jumps 23% to $3.12B as it launches $1.5B annual savings plan

AstraZeneca reported a 23% rise in third-quarter net profit and launched a programme to save $1.5 billion a year. The British drugmaker said profit after tax reached $3.12 billion, driven largely by its cancer treatments. Revenue grew 7% to $16.2 billion, with oncology making up 48% of the total. Net profit for the first nine months was $8.7 billion. The savings programme will cost $2.0 billion before it delivers the yearly benefits. AstraZeneca said it would reinvest the savings in its drug pipeline. Chief executive Pascal Soriot said the company has "multiple potential blockbuster" drugs in late-stage development. AstraZeneca remains on track for its 2030 target of $80 billion in annual revenue, up from nearly $59 billion last year. Its shares rose 3.1% in London.